ACRS Aclaris Therapeutics
- 1.190
- +0.010+0.85%
Aclaris Therapeutics News
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Results clearly exceeded expectations, with a su
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Aclaris Therapeutics(ACRS.US) Q1 2024 Earnings Conference
The following is a summary of the Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript:Financial Performance:Aclaris Therapeutics had $161 million in cash, cash equivalents and marketabl
Q1 2024 Aclaris Therapeutics Inc Earnings Call
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics | 10-Q: Quarterly report
Aclaris Therapeutics Corporate Update Conference Call
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, Vs. Street Est of $2M
04:07 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M
Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 42.86 percent increase over losses of
Aclaris Therapeutics 1Q Loss $16.9M >ACRS
Aclaris Therapeutics 1Q Loss $16.9M >ACRS
Press Release: Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET T
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
PDF Version Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update May 7, 2024 - Progressing ATI-2138 into Atopic Dermatitis -- Management to Host Con
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results On May 7, 2024 and to Provide Corporate Update
PDF Version Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update April 30, 2024 WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) --
Press Release: Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer PR Newswire CAMBRIDGE, Mass., April 23, 2024 CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutic
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034 by Drug Class, Application and Region - Featuring Eli Lilly & Company, Amgen, Johnson & Johnson, and Aclaris Therapeutics Among Others
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
Aclaris Therapeutics (ACRS) has provided an update.
Biotech's Role in Addressing the Pancreatic Cancer Emergency
USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today....
Analysis
Price Target
No Data
